ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 306 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.19 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,320,761 | -34.8% | 86,370 | -13.5% | 0.01% | -42.9% |
| Q2 2023 | $3,559,616 | +32.6% | 99,821 | -5.6% | 0.01% | +7.7% |
| Q1 2023 | $2,685,161 | -14.5% | 105,715 | +36.5% | 0.01% | -38.1% |
| Q4 2022 | $3,140,479 | -99.9% | 77,428 | +5.4% | 0.02% | +10.5% |
| Q3 2022 | $2,426,927,000 | +14.6% | 73,432 | +22.1% | 0.02% | 0.0% |
| Q2 2022 | $2,117,001,000 | +1.1% | 60,125 | +32.0% | 0.02% | +11.8% |
| Q1 2022 | $2,094,568,000 | +40.0% | 45,544 | +90.0% | 0.02% | +54.5% |
| Q3 2021 | $1,496,447,000 | +18.7% | 23,970 | -17.9% | 0.01% | -45.0% |
| Q2 2020 | $1,260,629,000 | +575529.7% | 29,188 | +284.1% | 0.02% | +566.7% |
| Q1 2020 | $219,000 | -97.9% | 7,600 | -95.3% | 0.00% | -96.3% |
| Q4 2019 | $10,283,000 | +91.7% | 162,126 | -14.8% | 0.08% | +68.8% |
| Q3 2019 | $5,363,000 | +1.5% | 190,301 | -4.6% | 0.05% | 0.0% |
| Q2 2019 | $5,283,000 | +173.0% | 199,375 | +89.1% | 0.05% | +182.4% |
| Q1 2019 | $1,935,000 | – | 105,433 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,328 | $51,213,000 | 30.37% |
| JOHNSON & JOHNSON | 3,260,869 | $203,576,000 | 17.86% |
| ACT CAPITAL MANAGEMENT, LLC | 194,000 | $12,111,000 | 6.28% |
| Aquilo Capital Management, LLC | 527,926 | $32,958,000 | 5.99% |
| Evolutionary Tree Capital Management, LLC | 105,491 | $6,586,000 | 2.92% |
| ACUTA CAPITAL PARTNERS, LLC | 121,500 | $7,585,000 | 2.68% |
| L1 Capital Pty Ltd | 297,915 | $18,599,000 | 2.31% |
| Avidity Partners Management LP | 673,700 | $42,059,000 | 0.93% |
| Hood River Capital Management LLC | 338,734 | $21,147,000 | 0.65% |
| Tygh Capital Management, Inc. | 64,127 | $4,003,000 | 0.54% |